FR05C0021I2 - - Google Patents

Info

Publication number
FR05C0021I2
FR05C0021I2 FR05C0021C FR05C0021C FR05C0021I2 FR 05C0021 I2 FR05C0021 I2 FR 05C0021I2 FR 05C0021 C FR05C0021 C FR 05C0021C FR 05C0021 C FR05C0021 C FR 05C0021C FR 05C0021 I2 FR05C0021 I2 FR 05C0021I2
Authority
FR
France
Prior art keywords
pcv
orfs
antigen
preparation
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR05C0021C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health France SAS
Original Assignee
Merial SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27253376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR05C0021(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR9712382A external-priority patent/FR2769321B1/fr
Priority claimed from FR9800873A external-priority patent/FR2769322B1/fr
Priority claimed from FR9803707A external-priority patent/FR2776294B1/fr
Application filed by Merial SAS filed Critical Merial SAS
Publication of FR05C0021I1 publication Critical patent/FR05C0021I1/fr
Application granted granted Critical
Publication of FR05C0021I2 publication Critical patent/FR05C0021I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/02—Making cheese curd
    • A23C19/032—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin
    • A23C19/0321—Propionic acid bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/02—Making cheese curd
    • A23C19/032—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin
    • A23C19/0323—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin using only lactic acid bacteria, e.g. Pediococcus and Leuconostoc species; Bifidobacteria; Microbial starters in general
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16741—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10061—Methods of inactivation or attenuation
    • C12N2750/10064—Methods of inactivation or attenuation by serial passage

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
FR05C0021C 1997-10-03 2005-04-26 Active FR05C0021I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9712382A FR2769321B1 (fr) 1997-10-03 1997-10-03 Nouveaux circovirus porcins, vaccins et reactifs de diagnostics
FR9800873A FR2769322B1 (fr) 1997-10-03 1998-01-22 Nouveaux circovirus porcins, vaccins et reactifs de diagnostic
FR9803707A FR2776294B1 (fr) 1998-03-20 1998-03-20 Nouveaux circovirus porcins ; vaccins et reactifs de diagnostic
PCT/FR1998/002107 WO1999018214A1 (fr) 1997-10-03 1998-10-01 Circovirus porcins, vaccins et reactifs de diagnostic

Publications (2)

Publication Number Publication Date
FR05C0021I1 FR05C0021I1 (fr) 2005-05-27
FR05C0021I2 true FR05C0021I2 (fr) 2005-10-21

Family

ID=27253376

Family Applications (1)

Application Number Title Priority Date Filing Date
FR05C0021C Active FR05C0021I2 (fr) 1997-10-03 2005-04-26

Country Status (21)

Country Link
US (1) US6368601B1 (fr)
EP (4) EP1741785B1 (fr)
JP (5) JP5008218B2 (fr)
KR (4) KR100904852B1 (fr)
CN (2) CN101724606B (fr)
AT (3) ATE245191T1 (fr)
AU (1) AU756554C (fr)
BR (1) BR9812845B1 (fr)
CA (1) CA2305623C (fr)
CY (3) CY1110359T1 (fr)
DE (7) DE69839227T2 (fr)
DK (4) DK1281760T5 (fr)
ES (4) ES2302885T3 (fr)
FR (1) FR05C0021I2 (fr)
HK (1) HK1095161A1 (fr)
HU (2) HU226247B1 (fr)
NL (1) NL300326I2 (fr)
PL (1) PL198506B1 (fr)
PT (4) PT1281760E (fr)
UA (1) UA78180C2 (fr)
WO (1) WO1999018214A1 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2781159B1 (fr) * 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
US6517843B1 (en) * 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US7192594B2 (en) * 1997-10-03 2007-03-20 Merial Limited Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
US6391314B1 (en) * 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
US7211379B2 (en) * 1997-10-03 2007-05-01 Merial Sas Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
US20060029617A1 (en) * 1997-10-03 2006-02-09 Charreyre Catherine E Porcine circovirus and Helicobacter combination vaccines and methods of use
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US20040062775A1 (en) * 1997-12-05 2004-04-01 Agence Francaise De Securite Sanitaire Des Aliments Circovirus sequences associated with piglet weight loss disease (PWD)
PT1037909E (pt) * 1997-12-11 2007-09-07 Merial Sas Síndrome multi-sistémica do definhamento pós-desmame de porcos
EP1816200B1 (fr) * 1997-12-11 2016-03-09 Merial Virus de syndrome de dépérissement post-sevrage pour cochons
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
US6943152B1 (en) 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
ES2170622B1 (es) * 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
MXPA02012352A (es) * 2000-06-15 2004-09-06 Purdue Research Foundation Vacuna para temblores congenitos en cerdos.
US7018638B2 (en) * 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
MXPA03008810A (es) * 2001-03-27 2004-02-17 Univ Saskatchewan Metodos para cultivar circovirus.
CN100346826C (zh) 2001-07-20 2007-11-07 乔治亚大学研究基金会 通过核蛋白在磷酸化位点突变的减弱狂犬病病毒用于抗狂犬病的接种以及在cns中的基因治疗
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
ME00810B (fr) * 2002-08-26 2012-03-20 Zoetis Services Llc Vaccin contre les infections de l'appareil genital et du systeme respiratoire chez les bovins
KR20040021988A (ko) * 2002-09-06 2004-03-11 서상희 바이러스 증식용 돼지 신장 상피 세포주, 및 이의 용도
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US7833707B2 (en) * 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
ES2589928T3 (es) * 2005-04-13 2016-11-17 Merial, Inc. Procedimiento para la producción de circovirus porcino
EP1792996A1 (fr) * 2005-12-01 2007-06-06 Consejo Superior de Investigaciones Cientificas Acides nucléiques encodant des vaccins contre le virus du syndrome reproductif et respiratoire porcin (PRRSV)
TWI528970B (zh) 2005-12-29 2016-04-11 百靈佳殷格翰家畜藥品公司 多價第二型豬環狀病毒（ｐｃｖ２）免疫組合物及製備該組合物之方法
ES2553254T3 (es) * 2005-12-29 2015-12-07 Boehringer Ingelheim Vetmedica, Inc. Uso de una composición inmunogénica de PCV2 para reducir los síntomas clínicos en cerdos
KR100870077B1 (ko) * 2006-10-27 2008-11-25 권영득 이유후 전신소모성증후군(ｐｍｗｓ)의 치료용 복합제조성물
WO2008073464A2 (fr) 2006-12-11 2008-06-19 Boehringer Ingelheim Vetmedica, Inc. Procédé efficace de traitement du circovirus porcin et des infections par lawsonia intracellularis
KR101619730B1 (ko) * 2006-12-15 2016-05-12 베링거잉겔하임베트메디카인코퍼레이티드 Ｐｃｖ2 항원을 이용한 돼지의 치료
EP1941903A1 (fr) * 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxie et traitement du PRDC
EP1958644A1 (fr) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prévention et traitement du PCVD subclinique
DK2155246T3 (da) * 2007-05-11 2013-04-02 Temasek Life Sciences Lab Ltd Fremstilling af en homogen cellelinje højtolerant til porcine circovirus type 2 (pcv2)-infektion
KR100948127B1 (ko) * 2007-06-27 2010-03-18 주식회사 중앙백신연구소 복합호흡기 질환 돼지의 조직유제를 함유하는 백신 조성물
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
US7829274B2 (en) * 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
BRPI0821286A8 (pt) * 2007-12-21 2017-08-15 Wyeth Llc Métodos e composições para imunizar porcos contra circovirus suino
WO2009088950A2 (fr) * 2007-12-31 2009-07-16 Boehringer Ingelheim Vetmedica, Inc. Particule de type virus pcv2 orf2 avec insertion d'acides aminés étrangers
EP2242511A4 (fr) 2008-01-23 2012-10-24 Boehringer Ingelheim Vetmed Compositions immunogènes de mycoplasma hyopneumoniae pcv2, et procédés de production de telles compositions
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
TWI508974B (zh) 2010-12-22 2015-11-21 Sbc Virbac Ltd 豬第二型環狀病毒(Porcine Circovirus Type 2)、含彼之免疫組合物、檢測套組及其應用
EP2564869A1 (fr) 2011-09-02 2013-03-06 Ceva Sante Animale Protéines de capside synthétiques et leurs utilisations
EP2789346A1 (fr) 2013-04-11 2014-10-15 CEVA Santé Animale SA Vaccins et polypeptides de fusion
EP2994162B1 (fr) 2013-05-08 2021-04-07 Pharmgate Biologics Inc. Vaccin pour pcv2 et mycoplasme
CN105579060B (zh) 2013-09-25 2021-03-16 硕腾服务有限责任公司 Pcv2b趋异株疫苗组合物以及使用方法
JP6778104B2 (ja) 2013-10-02 2020-10-28 ベーリンガー・インゲルハイム・アニマル・ヘルス・ユーエスエー・インコーポレイテッドＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ａｎｉｍａｌ Ｈｅａｌｔｈ Ｕｓａ Ｉｎｃ． Ｐｃｖ２ ｏｒｆ２タンパク質変種および前記を含むウイルス様粒子
CN104383527A (zh) * 2014-11-18 2015-03-04 天津瑞普生物技术股份有限公司 一种猪圆环病毒2型灭活冻干疫苗的制备方法
EP3034609A1 (fr) 2014-12-19 2016-06-22 Ceva Sante Animale Virus de recombinaison de la variole porcine et vaccins
WO2016183423A1 (fr) 2015-05-14 2016-11-17 Merial Inc. Procédé pour la production de vaccins contre le circovirus porcin et vaccins contre le pcv2
EP3254692A1 (fr) 2016-06-10 2017-12-13 Ceva Sante Animale Spv recombiné multivalent
US20200390878A1 (en) 2017-12-08 2020-12-17 Ceva Sante Animale Recombinant swinepox virus and vaccines
JP7162072B2 (ja) 2018-03-26 2022-10-27 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド 免疫原性組成物を製造する方法
BR112020025211A2 (pt) 2018-06-11 2021-03-09 Ceva Sante Animale Vacinação contra circovírus suíno
KR102124260B1 (ko) * 2018-10-19 2020-06-26 대한민국(관리부서 질병관리본부장) 신속 면역크로마토그래피법을 이용한 콜레라균 진단·탐지 키트 및 이를 위한 특이항체와 항체생산세포주
CN116157147A (zh) 2020-07-24 2023-05-23 勃林格殷格翰动物保健美国有限公司 组合猪疫苗

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4740468A (en) 1985-02-14 1988-04-26 Syntex (U.S.A.) Inc. Concentrating immunochemical test device and method
US5030558A (en) 1986-11-07 1991-07-09 Syntex (U.S.A.) Inc. Qualitative immunochromatographic method and device
US5232835A (en) 1986-11-07 1993-08-03 Syntex (U.S.A.) Inc. Qualitative immunochromatographic method and device
CA1303983C (fr) 1987-03-27 1992-06-23 Robert W. Rosenstein Essai en phase solide
DE560410T1 (de) 1987-04-27 2001-12-20 Unilever Nv Testgerät zur Durchführung von spezifischen Bindungsprüfungen.
US4855240A (en) 1987-05-13 1989-08-08 Becton Dickinson And Company Solid phase assay employing capillary flow
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
PT88590B (pt) * 1987-09-28 1993-04-30 Beecham Inc Processo para a preparacao de uma composicao vacina inactivada
ES2200016T3 (es) 1989-03-21 2004-03-01 Vical Incorporated Expresion de secuencias polinucleotidicas exogenas en un vertebrado.
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
US5141850A (en) 1990-02-07 1992-08-25 Hygeia Sciences, Inc. Porous strip form assay device method
WO1991018627A1 (fr) 1990-05-29 1991-12-12 Smithkline Beecham Corporation Vaccin contre la pneumonie porcine et procede de preparation dudit vaccin
US5238652A (en) 1990-06-20 1993-08-24 Drug Screening Systems, Inc. Analytical test devices for competition assay for drugs of non-protein antigens using immunochromatographic techniques
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
US5266497A (en) 1990-08-31 1993-11-30 Japan Synthetic Rubber Co., Ltd. Immunochromatographic assay with improved colored latex
US5451504A (en) 1991-07-29 1995-09-19 Serex, Inc. Method and device for detecting the presence of analyte in a sample
ES2083764T5 (es) 1991-10-14 2009-04-01 Intervet International Bv Vacuna para el sindrome respiratorio reproductivo porcino (srrp) y diagnostico.
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
DE9204303U1 (de) 1992-03-30 1992-06-25 Marx, Günter Wolfgang, 7953 Bad Schussenried Trainingsgerät
EP0571648A1 (fr) 1992-05-26 1993-12-01 Chung-Nan Weng Vaccin protégeant contre la pneumonie mycoplasmique
US6592873B1 (en) * 1992-10-30 2003-07-15 Iowa State University Research Foundation, Inc. Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids
FR2700957B1 (fr) 1993-01-29 1995-03-03 Seppic Sa Composition de vaccin sous-unitaire recombinant vivant et procédé de préparation.
ES2152304T3 (es) 1993-02-08 2001-02-01 Bayer Ag Procedimiento para el crecimiento del virus del sindrome reproductivo y respiratorio porcino y su uso en vacunas.
FR2702373B1 (fr) 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
EP0620277A1 (fr) 1993-03-18 1994-10-19 Merck & Co. Inc. Acides nucléiques comme produits pharmaceutiques
ES2074950B1 (es) 1993-09-17 1996-03-16 Iberica Cyanamid Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda.
EP1170368B1 (fr) 1994-01-27 2010-07-28 University Of Massachusetts Medical Center Immunisation par inoculation d'une unité de transcription d'ADN
ATE206455T1 (de) * 1994-04-11 2001-10-15 Akzo Nobel Nv Europäische vakzinstämme des fortplanzungs- atmungs-syndromsvirus des schweins
CA2196865C (fr) * 1994-08-05 2001-07-03 Karl P. Schneider Trepan a auto-chaufreinage
FR2781159B1 (fr) * 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
PT1037909E (pt) * 1997-12-11 2007-09-07 Merial Sas Síndrome multi-sistémica do definhamento pós-desmame de porcos
KR100298125B1 (ko) * 1999-04-15 2001-09-13 정명식 구리의 화학 증착에 유용한 유기 구리 전구체

Also Published As

Publication number Publication date
DK1386617T3 (da) 2008-07-07
DE69816460T2 (de) 2004-05-27
JP2012193179A (ja) 2012-10-11
HU230340B1 (hu) 2016-02-29
ES2203984T3 (es) 2004-04-16
AU756554C (en) 2003-09-18
CY1108113T1 (el) 2014-02-12
EP1741785A1 (fr) 2007-01-10
EP1019510A1 (fr) 2000-07-19
EP1019510B1 (fr) 2003-07-16
UA78180C2 (uk) 2007-03-15
EP1386617A1 (fr) 2004-02-04
JP2001519159A (ja) 2001-10-23
FR05C0021I1 (fr) 2005-05-27
JP5869658B2 (ja) 2016-02-24
PT1019510E (pt) 2003-11-28
EP1281760A1 (fr) 2003-02-05
NL300326I2 (nl) 2008-04-01
DK1741785T3 (da) 2014-11-10
ES2302885T3 (es) 2008-08-01
CY1115749T1 (el) 2017-01-25
KR20090051274A (ko) 2009-05-21
DE69830858T4 (de) 2006-12-21
KR100904852B1 (ko) 2009-06-25
AU9355598A (en) 1999-04-27
AU756554B2 (en) 2003-01-16
HU0800330D0 (en) 2008-07-28
KR20010030930A (ko) 2001-04-16
HU226247B1 (en) 2008-07-28
KR20060079256A (ko) 2006-07-05
DE05014998T1 (de) 2008-11-20
HK1095161A1 (en) 2007-04-27
DE69839227D1 (de) 2008-04-17
ES2524359T3 (es) 2014-12-05
CN100584948C (zh) 2010-01-27
JP2008086317A (ja) 2008-04-17
ATE387914T1 (de) 2008-03-15
EP1281760B1 (fr) 2005-07-13
HUP0003756A3 (en) 2003-03-28
CN1278301A (zh) 2000-12-27
JP2011135875A (ja) 2011-07-14
EP1741785B1 (fr) 2014-10-01
HUP0003756A2 (hu) 2001-02-28
JP5008218B2 (ja) 2012-08-22
PT1281760E (pt) 2005-11-30
CA2305623C (fr) 2008-04-01
ATE299531T1 (de) 2005-07-15
DE69830858T2 (de) 2006-04-20
DE69830858D1 (de) 2005-08-18
BR9812845A (pt) 2000-08-08
DE122008000069I1 (de) 2009-11-05
DE69839227T2 (de) 2009-03-12
JP2015109840A (ja) 2015-06-18
NL300326I1 (nl) 2008-03-03
JP4680245B2 (ja) 2011-05-11
EP1386617B1 (fr) 2008-03-05
BR9812845B1 (pt) 2010-03-09
WO1999018214A1 (fr) 1999-04-15
DE69816460D1 (de) 2003-08-21
DK1281760T3 (da) 2005-10-31
CA2305623A1 (fr) 1999-04-15
ATE245191T1 (de) 2003-08-15
CN101724606B (zh) 2016-02-24
DK1019510T3 (da) 2003-11-10
KR100944144B1 (ko) 2010-02-24
DK1281760T5 (da) 2006-04-18
PT1386617E (pt) 2008-06-17
KR20080023271A (ko) 2008-03-12
CY1110359T1 (el) 2015-04-29
PL198506B1 (pl) 2008-06-30
PL339631A1 (en) 2001-01-02
ES2246001T3 (es) 2006-02-01
PT1741785E (pt) 2014-11-13
EP1281760B9 (fr) 2005-12-28
KR100736129B1 (ko) 2007-07-06
US6368601B1 (en) 2002-04-09
JP5362750B2 (ja) 2013-12-11
CN101724606A (zh) 2010-06-09
DE122005000009I1 (de) 2005-08-04
KR100854615B1 (ko) 2008-08-27

Similar Documents

Publication Publication Date Title
FR05C0021I2 (fr)
Corona Gutierrez et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus
Hahn et al. Construction of recombinant swinepox viruses and expression of the classical swine fever virus E2 protein
Lenz et al. Papillomavirus virus‐like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells
Guo et al. Expression and self-assembly in baculovirus of porcine enteric calicivirus capsids into virus-like particles and their use in an enzyme-linked immunosorbent assay for antibody detection in swine
AU2011306957C1 (en) BVDV vaccine
GR860915B (en) Expression and diagnostic use of gag encoded peptides which are immunologically reactive with antibodies to lav
RU2000111496A (ru) Новые цирковирусы свиней, вакцины и реагенты для диагностики
Li et al. A Semliki Forest virus replicon vectored DNA vaccine expressing the E2 glycoprotein of classical swine fever virus protects pigs from lethal challenge
Sun et al. Comparison of the protective efficacy of recombinant adenoviruses against classical swine fever
Kos et al. Induction of primary anti‐viral cytotoxic T cells by in vitro stimulation with short synthetic peptide and interleukin‐7
Zelnik et al. An enzyme‐linked immunosorbent assay (ELISA) for detection of Marek's disease virus‐specific antibodies and its application in an experimental vaccine trial
Moennig et al. Prolonged persistence of cytopathogenic bovine viral diarrhea virus (BVDV) in a persistently viremic cattle
CN108218982A (zh) 人巨细胞病毒anti-UL148多克隆抗体及其制备方法与应用
TWI328039B (fr)
KR100785397B1 (ko) 인체 파필로마 바이러스 유사 입자를 생산하는 재조합아데노바이러스 벡터 및 자궁경부암 생백신
Kaden et al. Oral vaccination against classical swine fever with a chimeric Pestivirus: comparative investigations of liquid and lyophilized virus
Callebaut et al. Construction of a recombinant adenovirus for the expression of the glycoprotein S antigen of porcine respiratory coronavirus
CA2246802C (fr) Antigene combine a un cytomegalovirus humain et son utilisation
EP1314738A1 (fr) Pseudovirions comprenant des capsides du virus, des histones et d'acides nucléiques comme agents thérapeutiques
Wasito et al. Development of DNA recombinant vaccine for type 1 bovine viral
Pither et al. Mapping of B and T Cell Epitopes on the Epstein-Barr Virus Receptor Ligand Gp340: A Candidate Subunit Vaccine
Hassanain et al. Impact of Local Toxoplasma gondii Strain on Herpes simplex Virus Propagated in Tissue Culture